Stock Analysis
TransMedics Group, Inc. (TMDX) Stock Analysis
TransMedics Group, Inc. (TMDX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
TransMedics Group, Inc. (TMDX) currently has an AIQ Score of 39/100, indicating a bearish setup. Quality is the strongest factor at 64/100. Momentum is the weakest current factor at 23/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
TMDX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $65.99 |
| AIQ Score | 39/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $2.84B |
| P/E Ratio (TTM) | 18.61 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $0.42 |
| Revenue (quarter ended 2026-06-30) | $189.95M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.88 |
| Volume | 900.11K |
| 52-week range | $60.11-$156.00 |
| RSI 14 | 27.28 |
| 50-Day SMA | $82.15 |
| 200-Day SMA | $94.86 |
| Analyst Price Target | $102.53 |
| Next Earnings | Nov 5, 2026 |
TMDXTransMedics Group, Inc.
Healthcare / Medical - Devices
Low Priority
Relative Laggard
Latest quote
- Momentum23
- Value32
- Quality64
- Risk resilience32
- Sentiment—
TMDX Stock Analysis Summary
TransMedics Group, Inc. (TMDX) currently has an AIQ Score of 39/100, indicating a bearish setup. Quality is the strongest factor at 64/100. Momentum is the weakest current factor at 23/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, TMDX has AIQ Score of 39/100 with Quality base of 64/100 and fading Momentum at 23/100. Wait for component alignment before adding exposure.
Quality (64/100) leads while Momentum (23/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -1.68% stock move · TMDX classified in Medical - Devices.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is TMDX Bullish or Bearish Right Now?
TMDX currently has a bearish overall setup. Quality is the strongest factor at 64/100, while Momentum is weakest at 23/100. The current evidence suggests a defensive setup.
- - Quality is supportive at 64/100.
- - Analyst target implies +55.37% upside from the latest quote.
- - Value is the current constraint at 32/100.
- - Momentum is weak at 23/100.
- - Risk Resilience is weak at 32/100.
- - Price is -29.24% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (37 vs 6).
Current Consensus
TMDX's Technical Analysis Consensus is currently Strong Sell, with 6 buy, 2 neutral, and 37 sell votes. TMDX's 14-day RSI is 27.28, which places the stock in an oversold momentum range. TMDX's beta is 1.88, indicating greater market sensitivity than the broad market.
What Changed in TMDX?
The largest recent change in TMDX is Momentum moving down by 5.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the TMDX Outlook?
The current bearish outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
TMDX Decision Framework
Public evidence layers, setup checks, and risk context for TransMedics Group, Inc..
TransMedics Group, Inc. (TMDX) Stock Analysis
TransMedics Group, Inc. has an AIQ Score of 39/100 in a Defensive regime. Quality is strongest at 64/100. Beta is 1.93, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | TMDX is in a Defensive AIQ regime with score 39/100. |
| Signal Conflict | The primary conflict is that quality leads at 64/100 while momentum lags at 23/100. |
| Factor Evidence | Momentum 23/100 · Value 32/100 · Quality 64/100 · Risk 32/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 64/100.
Momentum is 23/100 and RSI (14) is 27.3.
TMDX is in a Defensive regime at 39/100.
Risk factor is 32/100 with beta 1.93 and annual volatility 57.13%.
Current conflict: quality leads at 64/100 while momentum lags at 23/100.
TMDX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
TMDX Fundamentals
TMDX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
TMDX Technical Analysis
TMDX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
TMDX Stock Catalysts
Track TMDX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
TMDX Dividend Analysis
TMDX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
TMDX Financial Data
TMDX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
TMDX Risk Analysis
TMDX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
TMDX Stock News
TMDX stock news, market tone, recent headlines, and catalyst context.
TMDX vs Medical Devices Peers
Current peer cohort: TMDX · VTRS · WAT · XRAY · ZBH. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| TMDX Current stock | 39/100 | 32/100 | 23/100 | 32/100 | -0.99 | 57.13% | Current |
| VTRS Viatris | 59/100 | 73/100 | 76/100 | 62/100 | 1.98 | 32.45% | TMDX vs VTRS |
| WAT Waters Corporation | 57/100 | 32/100 | 90/100 | 66/100 | 1.02 | 35.26% | TMDX vs WAT |
| XRAY Dentsply Sirona | 51/100 | 73/100 | 53/100 | 52/100 | -0.45 | 47.92% | TMDX vs XRAY |
| ZBH Zimmer Biomet | 65/100 | 66/100 | 80/100 | 55/100 | -0.02 | 32.74% | TMDX vs ZBH |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 29, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts4 recent quarterly periods are available for review.
Checked Oct 31, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching TMDX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for TMDX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
TMDX Stock FAQ
What is TMDX stock price today?
TransMedics Group, Inc.'s current stock price is $65.99. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is TMDX bullish or bearish right now?
TMDX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is TMDX's market cap?
TMDX's market cap is $2.84B based on the latest completed market-close snapshot from Oct 30, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is TMDX's current P/E ratio?
TMDX's current P/E ratio is 18.61 based on the latest completed market-close snapshot from Oct 30, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is TMDX's RSI?
TMDX's 14-day RSI is 27.28 based on the latest completed market-close snapshot from Oct 30, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is TMDX above its 50-day and 200-day moving averages?
TMDX is -18.30% from its 50-day SMA and -29.24% from its 200-day SMA based on the latest completed market-close snapshot from Oct 30, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is TMDX's next earnings date?
TMDX's next earnings date is currently listed as Nov 5, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does TMDX pay a dividend?
TMDX's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 30, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.